Phage and yeast display has yielded a staggering arsenal of multispecific antibodies, antibody-drug conjugates, immunotherapies, and numerous other constructs. The emergence of computational tools are being applied to improve selection, design, and efficacy of candidates and predictive measures of success in the translation to effective drug candidates. Newer, sophisticated methods of conditional activation approaches will allow biologics to hit the tumour before they become activated, reducing off-target toxicity and adverse events. The 11th Annual Display of Biologics conference is the cornerstone of the PEGS Europe Summit, and will highlight progress and approaches leading to new classes of therapy.

For more details on the conference, please contact:

Christina Lingham
Executive Director, Conferences and Fellow
Cambridge Healthtech Institute
Phone: (+1) 508-813-7570
Email: clingham@healthtech.com

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5452
Email: jgerardi@healthtech.com

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-1340
Email: ashleyparsons@healthtech.com

Conference Programs

• Display of Biologics
• Engineering Antibodies
• Machine Learning: Part 2

• Antibody-Based Therapies
• Emerging Targets & Approaches
• Membrane Protein Targets

• Safety & Efficacy
• Advancing Multispecifics
• Engineering Bispecifics

• Modulating the TME
• Innovative CAR T Therapy
• Next-Gen Immunotherapies

• Optimisation & Developability
• Analytical Characterisation
• Protein Stability & Formulation

• Data Science & Engineering
• Optimising Expression
• Process Development

• Intro to Machine Learning
• Machine Learning: Part 1
• Machine Learning: Part 2

• Antibody-Based Therapies
• Engineering Conjugates
• Next-Gen Immunotherapies

---